Research published today brings together for the first time the epidemiology and evolution of the SARS-CoV-2 virus in the UK during the first three years of the pandemic \u2013 including how variants emerged and spread.
The University of Oxford has launched a new global vaccine collaboration, backed by \u00a38 million funding from UK Research and Innovation (UKRI), and led by two PSI Principal Investigators.
The UK trial is the next step in the development of a vaccine to protect people against MERS \u2013 a deadly viral illness with no current vaccines and the potential to cause a pandemic.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
A new Future Vaccines Manufacturing Hub \u2013 co-led by University of Oxford and University College London \u2013 aims to make the UK the global centre for discovering and manufacturing next-generation vaccines.
A team of experts at the Pandemic Sciences Institute at the University of Oxford and Department of Statistics at the University of Warwick estimate the NHS COVID-19 app prevented around 1 million cases, 44,000 hospitalisations and 9,600 deaths during its first year.
The inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.
A vaccine developed by the Oxford Vaccine Group\u2019s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.
The UK\u2019s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium \u2013 in which the University of Oxford is a key partner \u2013 working together to develop better diagnostic tests, identify potential therapies and study vaccine effectiveness.
The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.
Oxford researchers are seeking participants for a trial to discover what happens when people who have either already had Covid-19 or who have been vaccinated are exposed to the original strain of virus
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.
The University of Oxford has today announced the launch of a new hub of global research collaboration and excellence, the Pandemic Sciences Institute. \r\n\r\nThe Pandemic Sciences Institute will harness the strong global research collaborations that the University of Oxford has developed over more than forty years. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats.
![\"AI](\"https://www.psi.ox.ac.uk/news-and-opinion/researchers-analyse-uk2019s-covid-19-infection-survey-data-to-tell-the-story-of-the-virus-genomic-evolution-and-spread/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n